{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:13:52Z","timestamp":1792671232516,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00dcB\u0130TAK","doi-asserted-by":"publisher","award":["120N552"],"award-info":[{"award-number":["120N552"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurochemistry International"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.neuint.2026.106146","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T08:00:44Z","timestamp":1773129644000},"page":"106146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Human Neuraminidase 3 reduces the severity of Tay-Sachs disease symptoms in a mouse model"],"prefix":"10.1016","volume":"195","author":[{"given":"Hande","family":"Bas\u0131rl\u0131","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0243-5011","authenticated-orcid":false,"given":"Volkan","family":"Seyrantepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuint.2026.106146_bib1","doi-asserted-by":"crossref","DOI":"10.1128\/AEM.00463-07","article-title":"Production of recombinant \u03b2-hexosaminidase A, a potential enzyme for replacement therapy for Tay-Sachs and Sandhoff diseases, in the methylotrophic yeast Ogataea minuta","volume":"73","author":"Akeboshi","year":"2007","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.neuint.2026.106146_bib2","doi-asserted-by":"crossref","DOI":"10.1172\/JCI183434","article-title":"CNS-targeted base editing of the major late-onset Tay-Sachs mutation alleviates disease in mice","volume":"135","author":"Allende","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.neuint.2026.106146_bib3","article-title":"Cytokines in Gaucher's disease","volume":"10","author":"Barak","year":"1999","journal-title":"Eur. Cytokine Netw."},{"key":"10.1016\/j.neuint.2026.106146_bib4","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency \u2014 macrophage-targeted glucocerebrosidase for gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuint.2026.106146_bib5","article-title":"Intravenous delivery for treatment of mucopolysaccharidosis type I: a comparison of AAV serotypes nine and rh10","volume":"24","author":"Belur","year":"2020","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.neuint.2026.106146_bib6","doi-asserted-by":"crossref","DOI":"10.1212\/01.wnl.0000194225.78917.de","article-title":"Substrate reduction therapy in the infantile form of Tay-Sachs disease","volume":"66","author":"Bembi","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neuint.2026.106146_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2010.09.004","article-title":"An open-label phase I\/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants)","volume":"102","author":"Clarke","year":"2011","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.neuint.2026.106146_bib8","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-020-01947-6","article-title":"GM2 ganglioside accumulation causes neuroinflammation and behavioral alterations in a mouse model of early onset Tay-Sachs disease","volume":"17","author":"Demir","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuint.2026.106146_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2023.1242814","article-title":"Characterization of a phenotypically severe animal model for human AB-Variant GM2 gangliosidosis","volume":"16","author":"Deschenes","year":"2023","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuint.2026.106146_bib10","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human \u03b1-Galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuint.2026.106146_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0241084","article-title":"Quantifying myelin content in brain tissue using color spatial light interference microscopy (cSLIM)","volume":"15","author":"Fanous","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.neuint.2026.106146_bib12","doi-asserted-by":"crossref","DOI":"10.3791\/58960","article-title":"Production, purification, and quality control for adeno-associated virus-based vectors","author":"Fripont","year":"2019","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.neuint.2026.106146_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41436-019-0451-z","article-title":"Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study","volume":"21","author":"Germain","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/j.neuint.2026.106146_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2022.10.004","article-title":"AAVrh10 vector corrects pathology in animal models of GM1 gangliosidosis and achieves widespread distribution in the CNS of nonhuman primates","volume":"27","author":"Hocquemiller","year":"2022","journal-title":"Mol. Ther., Methods Clin. Dev."},{"key":"10.1016\/j.neuint.2026.106146_bib15","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.omtm.2019.12.001","article-title":"AAVrh10 vector corrects disease pathology in MPS IIIA mice and achieves widespread distribution of SGSH in large animal brains","volume":"17","author":"Hocquemiller","year":"2020","journal-title":"Mol. Ther., Methods Clin. Dev."},{"key":"10.1016\/j.neuint.2026.106146_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2023.137610","article-title":"Adenosine A2A receptor antagonist KW6002 protects against A53T mutant alpha-synuclein-induced brain damage and neuronal apoptosis in Parkinson's disease mice by restoring autophagic flux","volume":"826","author":"Hu","year":"2024","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuint.2026.106146_bib17","doi-asserted-by":"crossref","DOI":"10.1038\/sj.bmt.1705155","article-title":"Allogeneic BMT followed by substrate reduction therapy in a child with subacute Tay-Sachs disease [5]","author":"Jacobs","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.neuint.2026.106146_bib18","doi-asserted-by":"crossref","DOI":"10.1055\/s-2005-837543","article-title":"Enzyme replacement therapy in classical infantile Pompe disease: results of a ten-month follow-up study","volume":"36","author":"Klinge","year":"2005","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.neuint.2026.106146_bib19","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1194\/jlr.M051839","article-title":"Renal sulfatides: sphingoid base-dependent localization and region-specific compensation of CerS2-dysfunction","volume":"55","author":"Marsching","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.neuint.2026.106146_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2018.07.014","article-title":"Inhibition of astrocytic adenosine receptor A2A attenuates microglial activation in a mouse model of Sandhoff disease","volume":"118","author":"Ogawa","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuint.2026.106146_bib21","doi-asserted-by":"crossref","DOI":"10.1089\/hum.2012.015","article-title":"Correction of brain oligodendrocytes by AAVrh.10 intracerebral gene therapy in metachromatic leukodystrophy mice","volume":"23","author":"Piguet","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.neuint.2026.106146_bib22","first-page":"276","article-title":"Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin","author":"Platt","year":"1997","journal-title":"Science (1979)"},{"key":"10.1016\/j.neuint.2026.106146_bib23","doi-asserted-by":"crossref","DOI":"10.1039\/C6CC01564F","article-title":"Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases","author":"S\u00e1nchez-Fern\u00e1ndez","year":"2016","journal-title":"Chem. Commun."},{"key":"10.1016\/j.neuint.2026.106146_bib24","doi-asserted-by":"crossref","first-page":"20386","DOI":"10.1074\/jbc.M110641200","article-title":"Kidney sulfatides in mouse models of inherited glycosphingolipid disorders: determination by nano-electrospray ionization tandem mass spectrometry","volume":"277","author":"Sandhoff","year":"2002","journal-title":"JBC"},{"key":"10.1016\/j.neuint.2026.106146_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/ng1095-170","article-title":"Mouse models of Tay\u2013Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism","volume":"11","author":"Sango","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuint.2026.106146_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.neuint.2026.106146_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2017.09.012","article-title":"Murine Sialidase Neu3 facilitates GM2 degradation and bypass in mouse model of Tay-Sachs disease","volume":"299","author":"Seyrantepe","year":"2018","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuint.2026.106146_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay5947","article-title":"An atlas of the protein-coding genes in the human, pig, and mouse brain","volume":"367","author":"Sj\u00f6stedt","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.neuint.2026.106146_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2018.01663","article-title":"New approaches to Tay-Sachs disease therapy","author":"Solovyeva","year":"2018","journal-title":"Front. Physiol."},{"key":"10.1016\/j.neuint.2026.106146_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/sj.mt.6300049","article-title":"Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus Macaque-derived Adeno-associated virus vector","volume":"15","author":"Sondhi","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neuint.2026.106146_bib31","series-title":"JIMD Reports","article-title":"Haematopoietic stem cell transplantation arrests the progression of neurodegenerative disease in late-onset Tay-Sachs disease","author":"Stepien","year":"2018"},{"key":"10.1016\/j.neuint.2026.106146_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2015.00036","article-title":"Systemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal mice","volume":"8","author":"Tanguy","year":"2015","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuint.2026.106146_bib33","doi-asserted-by":"crossref","DOI":"10.1089\/hum.2013.238","article-title":"Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cdnas in children with mucopolysaccharidosis type IIIA disease: results of a phase I\/II trial","volume":"25","author":"Tardieu","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.neuint.2026.106146_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/S0065-2660(01)44081-8","article-title":"17. Naturally occurring mutations in GM2 gangliosidosis: a compendium","author":"Triggs-Raine","year":"2001","journal-title":"Adv. Genet."},{"key":"10.1016\/j.neuint.2026.106146_bib35","doi-asserted-by":"crossref","DOI":"10.1515\/hsz-2014-0301","article-title":"Innate immune responses in the brain of sphingolipid lysosomal storage diseases","author":"Vitner","year":"2015","journal-title":"Biol. Chem."},{"key":"10.1016\/j.neuint.2026.106146_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuint.2026.106146_bib37","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.273.1.66","article-title":"Specificity of mouse G(M2) activator protein and \u03b2-N- \u03b2-N-acetylhexosaminidases A and B. Similarities and differences with their human counterparts in the catabolism of G(M2)","volume":"273","author":"Yuziuk","year":"1998","journal-title":"JBC"}],"container-title":["Neurochemistry International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018626000379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197018626000379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T23:05:01Z","timestamp":1776121501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197018626000379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":37,"alternative-id":["S0197018626000379"],"URL":"https:\/\/doi.org\/10.1016\/j.neuint.2026.106146","relation":{},"ISSN":["0197-0186"],"issn-type":[{"value":"0197-0186","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human Neuraminidase 3 reduces the severity of Tay-Sachs disease symptoms in a mouse model","name":"articletitle","label":"Article Title"},{"value":"Neurochemistry International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuint.2026.106146","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106146"}}